Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

341. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. (PubMed)

Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10% and given from the day of admission until independent mobility had been achieved or for 3 mo, whichever was the sooner) was assessed in 160 elderly patients who had sustained a fracture of the femoral neck. Treatment significantly (...) reduced the frequency of deep venous thrombosis (D.V.T.), whether indicated by the 125I-fibrinogen test during life or assessed by detailed post-mortem studies. Pulmonary embolism was eliminated in treated patients, but the difference in mortality between the treatment and control groups was not significant, indicating that causes of death other than pulmonary embolism are of major importance in these elderly patients. A case is made out for prophylactic anticoagulation on a selective basis.

1976 Lancet

342. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. (PubMed)

Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. The efficacy of low-dose heparin in preventing fatal postoperative pulmonary embolism has been investigated in a multicentre prospective randomised trial. 4121 patients over the age of forty years undergoing a variety of elective major surgical procedures were included in the trial; 2076 of these were in the control group and 2045 patients received heparin. The two groups were well (...) matched for age, sex, weight, blood-group, and other factors which could predispose to the development of venous thromboembolism. 180 (4-4 %) patients died during the postoperative period, 100 in the control and 80 in the heparin group: 72% of deaths in the control and 66% in the heparin group had necropsy examination. 16 patients in the control group and 2 in the heparin group were found at necropsy to have died due to acute massive pulmonary embolism (P smaller than 0-005). In addition, emboli found

1975 Lancet Controlled trial quality: uncertain

343. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. (PubMed)

Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. 5536580 1971 01 15 2016 11 22 0098-7484 214 12 1970 Dec 21 JAMA JAMA Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. 2163-72 eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Fibrinolytic Agents 0 Serum Globulins 9001-32-5 Fibrinogen 9001-91-6 Plasminogen 9005-49-6 Heparin AIM IM Angiography Female Fibrinogen blood Fibrinolytic (...) Agents adverse effects therapeutic use Heart Failure complications Hematocrit Hemorrhage chemically induced Heparin adverse effects therapeutic use Humans Male Middle Aged Plasminogen blood Pulmonary Artery diagnostic imaging Pulmonary Embolism diagnosis drug therapy mortality Radionuclide Imaging Serum Globulins analysis Time Factors 1970 12 21 1970 12 21 0 1 1970 12 21 0 0 ppublish 5536580

1971 JAMA Controlled trial quality: predicted high